Clinical Research and Studies
Research underpins everything we do at BIOHIT HealthCare so that when our products come to market they are supported b the evidence needed to offer real benefit.
We have an active Research and Development department headed by a Scientific Board comprising experts in key areas of medicine, biochemistry and technology, who collaborate with the medical and scientific communities worldwide. We work closely with Academic and Clinical establishments to build robust evidence to support the uptake of our products and services, and to develop and transfer new technology for tomorrows healthcare systems.
BIOHIT also develops and shares study protocols, i.e., descriptions of clinical studies designed for validation of BIOHIT's diagnostic tests as well as for evaluation of therapeutic efficacy of BIOHIT's Acetium® capsule and lozenge products. This applies to both current and novel clinical indications.
In recent years the UK public health sector has embraced the opportunity to collaborate more with industry. Applying a combination of expert led clinical care and resources, with the technologies developed and marketed by BIOHIT, such collaborative partnerships have led to the discovery of new applications for diagnostic tests, evidence for the use and application of novel diagnostics and cutting edge research into cost effective strategies for the future.
Got an interesting research project?
Let us know how we can collaborate. BIOHIT is always looking for new ways to partner to build effective healthcare applications using its diagnostic and intervention products.
BIOHIT welcomes the opportunity to collaborate on basic and clinical research with a focus on developing strategies that address the priorities of national clinical needs. For example, in 2018 the Research Committee of the British Society of Gastroenterology launched its Clinical Research Strategy, setting out its vision for the future in terms of priority areas for clinical research. One of top three priorities for the Endoscopy Clinical Research Group is to explore how minimally invasive tests can help to stratify gastrointestinal cancer risk, whilst the IBD Clinical Research Group focuses on ways to optimise treatment and identifies markers of disease monitoring and prognosis. It is strategies such as these that BIOHIT aligns its research resources with. For example, the BIOHIT GastroPanel blood test is a non-invasive method for identifying those individuals at increased risk of gastric cancer by identifying the precancerous lesion atrophic gastritis, while our range of therapeutic drug monitoring assays and gut microbiota test may prove beneficial in predicting therapeutic success and outcoms in IBD.
We also help support specific projects that such as investigator-led research and clinical trials involving BIOHIT products and services, such as the PANTs study - a prospective observational study investigating personalised biological therapy in Crohn's Disease; Faecal Bile acid study - exploring the role of faecal bile acids in the management of bile acid diarrhoea; and GastroPanel Study - Gastropanel for early detection of gastric atrophy and gastric cancer.
Read more >>